Post-acute COVID-19 in three doses vaccinated autoimmune rheumatic diseases patients: frequency and pattern of this condition

Background: Data on post-acute COVID-19 in autoimmune rheumatic diseases (ARD) are scarce, focusing on a single disease, with variable definitions of this condition and time of vaccination. The aim of this study was to evaluate the frequency and pattern of post-acute COVID-19 in vaccinated patients with ARD using established diagnosis criteria. Methods: Retrospective evaluation of a prospective cohort of 108 ARD patients and 32 non-ARD controls, diagnosed with SARS-CoV-2 infection (RT-PCR/antigen test) after the third dose of the CoronaVac vaccine. Post-acute COVID-19 (≥4 weeks and >12 weeks of SARS-CoV-2 symptoms) were registered according to the established international criteria. Results: ARD patients and non-ARD controls, balanced for age and sex, had high and comparable frequencies of > 4 weeks post-acute COVID-19 (58.3% vs. 53.1%, p=0.6854) and > 12 weeks post-acute COVID-19 (39.8% vs. 46.9%, p=0.5419). Regarding > 4 weeks post-acute COVID-19, frequencies of ≥3 symptoms were similar in ARD and non-ARD controls (54% vs. 41.2%, p=0.7886), and this was also similar in > 12 weeks post-acute COVID-19 (68.3% vs. 88.2%, p=0.1322). Further analysis of the risk factors for > 4 weeks post-acute COVID-19 in ARD patients revealed that age, sex, clinical severity of COVID-19, reinfection, and autoimmune diseases were not associated with this condition (p>0.05). The clinical manifestations of post-acute COVID-19 were similar in both groups (p>0.05), with fatigue and memory loss being the most frequent manifestations. Conclusion: We provide novel data demonstrating that immune/inflammatory ARD disturbances after third dose vaccination do not seem to be a major determinant of post-acute COVID-19 since its pattern is very similar to that of the general population. Clinical Trials platform (NCT04754698).